Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants priority review for Bayer’s Stivarga marketing application for liver cancer
HCC is the most common form of liver cancer, a disease that affects nearly 40,000 patients in the United States and is the second deadliest form of cancer
HCC is the most common form of liver cancer, a disease that affects nearly 40,000 patients in the United States and is the second deadliest form of cancer
APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic
In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGR achieved robust and sustained, statistically significant improvements in hemoglobin A1c (HbA1c)
In addition, Shire’s former MRT employees, the group focused on the development of this technology since 2008, have joined RaNA to continue to advance the platform with lead
The clinical trial is evaluating the efficacy and safety of Quisinostat in platinum-resistant ovarian cancer in combination with Paclitaxel and Carboplatin. The detailed results will be presented in
Cannabics Pharmaceuticals chief scientist Eyal Ballan stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on
Charles Theuer, M.D., Ph.D., President and CEO of TRACON, said: “The SPA agreement represents a significant milestone for TRACON, as it provides us with a clearly defined development
The investment was led by C-Bridge Capital, joined by a number of new investors including QianHai Equity Investment FOF, FOCUS Media Jiangnanchun Foundation, WTT Investment, together with the
Together the two companies are projected to generate approximately $136 million dollars in revenue in 2016 and are projecting $156 million in revenue for 2017. F.A.S.T. will retain
The study is enrolling patients with non-small cell lung cancer (NSCLC) who have failed prior therapy. The trial will begin with a Phase 1 safety component, enrolling up